US Corporate Distress Financial Stress SEC Filings — April 24, 2026

24-04-2026

PDF Solutions, Inc. executed a First Amendment to its Credit Agreement on April 23, 2026, increasing the Revolving Credit Facility by $30,000,000 to a total commitment of $70,000,000 with Wells Fargo Bank, National Association as Administrative Agent and sole Lender. The amendment updates Schedule 1.1 (Commitments and Commitment Percentages) and conforms the agreement accordingly, effective upon satisfaction of conditions including executed documents, officer certificates, legal opinions, and lien searches. No borrowings or financial performance metrics are disclosed in the filing.

• ·Original Credit Agreement dated March 7, 2025.
• ·Effectiveness conditions include certificates of incorporation/good standing, board resolutions, opinions from Latham & Watkins LLP (New York law) and Woodburn and Wedge LLP (Nevada law), and UCC lien searches confirming assets free of liens except Permitted Liens.
• ·Subsidiary Guarantors: Cimetrix Incorporated, Cimetrix International, Inc., PDF Solutions Asia Services, Inc., PDF Solutions International Services, Inc., PDF Solutions Pacific Services, Inc., Securewise LLC.

24-04-2026

Bio Essence Corp (BIOE) entered into an Asset Purchase Agreement dated April 20, 2026, to acquire the MediFlow AI software platform (previously AcuVital) from Zhituo Software Co., Ltd, including all source code, IP, trademarks, and related assets, for a purchase price of $3.5 million in restricted common stock. The Board of Directors approved the transaction via unanimous consent resolution on April 21, 2026, authorizing CEO Yin Yan to execute it, with closing to occur within 45 days subject to conditions. No declines or negative metrics reported; the deal enhances BIOE's software capabilities without cash outlay.

• ·Closing conditions include Board approval (already obtained) and delivery of assignment documents
• ·Seller representations and warranties survive 18 months post-closing (IP-related survive statute of limitations)
• ·Agreement governed by California law; exclusive venue in California courts
• ·Shares issued under Section 4(a)(2)/Regulation D exemption as restricted securities under Rule 144

24-04-2026

Trane Technologies plc, through its subsidiaries, entered into a new $1.5 billion senior unsecured revolving credit agreement on April 23, 2026, with a term through April 23, 2031, replacing the $1 billion facility from 2022 that was terminated effective the same date. The new facility, arranged by JPMorgan Chase Bank, N.A. and others, will fund working capital, commercial paper programs, general corporate purposes, and repayment of the prior agreement. Obligations are guaranteed by multiple Trane entities on a senior basis.

• ·New facility maturity: April 23, 2031
• ·Prior facility expiration: April 25, 2027
• ·Contains customary negative covenants, affirmative covenants, and events of default

24-04-2026

Accenture plc, as guarantor, along with borrowers Accenture Capital Inc., Accenture Global Capital Designated Activity Company, and Accenture Finance Limited, entered into a five-year Credit Agreement dated April 22, 2026, with Bank of America, N.A. as Administrative Agent and other lenders including JPMorgan Chase Bank, N.A., Barclays Bank PLC, BNP Paribas, Citibank, N.A., and Société Générale as arrangers. The agreement includes provisions for loans, letters of credit, and commitments detailed in schedules, with no specific facility size disclosed in the provided filing excerpt. This represents a standard refinancing or expansion of credit facilities with neutral implications.

• ·Deal CUSIP: 00430VAS0
• ·Facility CUSIP: 00430VAT8
• ·Filing items: 1.01, 1.02, 2.03, 9.01
• ·Schedules include 2.01 Commitments and 2.03 Letter of Credit Commitments

24-04-2026

Triller Group Inc. received a delisting determination letter from Nasdaq on April 17, 2026, for failing to meet the Minimum Bid Price Requirement under Nasdaq Listing Rule 5550(a)(2), as its common stock closing bid price remained below $1 per share for 30 consecutive business days ending December 29, 2025, with no compliance regained during the 180-day cure period starting June 30, 2025. Trading had previously been suspended from December 30, 2025, to April 15, 2026, due to noncompliance with the Periodic Filing Rule but resumed after filing its 10-K for the year ended December 31, 2025. The matter was remanded by the Listing Council to the Nasdaq Hearings Panel on April 21, 2026, with the Company planning to submit a response on April 24, 2026, requesting an exception period under Rule 5815(c)(1)(A), though no assurance of success is provided.

• ·Previous noncompliance: Nasdaq Listing Rule 5250(c)(1) (Periodic Filing Rule), resolved by filing 10-K for year ended December 31, 2025.
• ·Listing Council remanded bid price matter to Nasdaq Hearings Panel on April 21, 2026; Council may review and stay any delisting decision due to procedural history.
• ·Company ineligible for standard additional 180-day compliance period.

24-04-2026

On April 24, 2026, Virgin Galactic Holdings, Inc. entered into a Supplemental Indenture with subsidiary guarantors and Wilmington Savings Fund Society, FSB, amending the December 18, 2025 indenture for its existing 9.80% First Lien Notes due 2028. The amendments are technical, aimed at providing greater flexibility in connection with redemptions, without modifying the redemption price or payment obligations. No financial impacts or changes to obligations were reported.

• ·Original Indenture dated December 18, 2025.
• ·Supplemental Indenture filed as Exhibit 4.1.

24-04-2026

The Elmet Group Co. announced the pricing of its upsized initial public offering of approximately 8.6 million shares of common stock at $14.00 per share, generating $120.0 million in gross proceeds (net proceeds of approximately $109.0 million after expenses). The underwriters have a 30-day option to purchase up to an additional 1.3 million shares. Shares are expected to begin trading on Nasdaq Capital Market under ticker 'ELMT' on April 23, 2026, with closing on April 24, 2026; net proceeds will be used to repay debt, growth capital, working capital, and general corporate purposes.

• ·Underwriters: Cantor (lead book-running manager), Needham & Company and Canaccord Genuity (joint book-running managers), Roth Capital Partners (co-manager).
• ·Registration statement effective April 22, 2026.
• ·Elmet operates in Aerospace, Defense and Government, Industrial, Medical, Semiconductor and Electronics, and Energy industries.

24-04-2026

Altimmune, Inc. entered into an underwriting agreement on April 22, 2026, with Leerink Partners LLC and Barclays Capital Inc. to issue and sell 64,250,000 shares of common stock at $3.00 per share and pre-funded warrants to purchase up to 10,750,000 shares at $2.999 per warrant, each accompanied by common stock warrants. The offering closed on April 24, 2026, generating net proceeds of approximately $211.2 million, which will fund the clinical development of pemvidutide including its global pivotal Phase 3 trial in MASH, pre-commercial activities, and general corporate purposes. No declines or flat performance metrics were reported.

• ·Common stock warrants exercisable until the earlier of fifth anniversary or 45 days after Phase 3 pemvidutide MASH trial data readout.
• ·Pre-funded warrants do not expire and are exercisable immediately subject to ownership limits.
• ·Offering conducted under registration statements File Nos. 333-291329 (effective Dec 5, 2025), 333-285355 (effective Mar 13, 2025), and 333-295254 (effective Apr 22, 2026).

24-04-2026

SHF Holdings received a Nasdaq notice on April 22, 2026, for failing to maintain a $1.00 minimum closing bid price for its Common Stock over 30 consecutive business days, granting 180 days until October 19, 2026, to regain compliance or risk delisting, with no immediate impact on trading. Sundie Seefried resigned from the Board on April 20, 2026 (no disagreements noted), leading to appointments of Tyler Klimas and Sean Tonner as directors and expansion of the Board from five to six members. In ongoing litigation over the Abaca acquisition, a court on April 23, 2026, denied the Company's summary judgment motion in full, granted counterclaimants' motions on key issues including breach of merger agreement, with damages to be determined and $3.0 million remaining in court registry.

• ·Nasdaq Marketplace Rule 5550(a)(2) violated; potential second 180-day extension if eligible
• ·Litigation case: SHF Holdings, Inc. v. Daniel Roda, Gregory W. Ellis, and James R. Carroll, Case No. 2024CV33187 (District Court for the City and County of Denver, Colorado)
• ·Company address: 1526 Cole Blvd., Suite 250, Golden, Colorado 80401

24-04-2026

Bumble Inc. refinanced its existing Credit Agreement dated January 29, 2020, by entering a new Term Loan Facility and using its net proceeds along with cash on hand to fully repay and terminate all outstanding indebtedness under the prior agreement on the Closing Date. The prior Credit Agreement involved Citibank, N.A. as administrative agent, with details referenced from the Company's 10-K filed March 16, 2026. No specific financial metrics such as loan amounts or terms were disclosed in this filing.

• ·Prior Credit Agreement dated January 29, 2020, described in Item 7 of 10-K for year ended December 31, 2025, filed March 16, 2026
• ·References quarter ending June 30, 2026

24-04-2026

Spire Global Canada Subsidiary Corp., a wholly owned subsidiary of Spire Global, Inc., received immediate termination notice on April 23, 2026, for its WildFireSat satellite constellation contract with the Canadian government (PWGS for the Canadian Space Agency), which had a potential aggregate value of Can$71.8 million if all milestones were met. The termination was for convenience, with no further milestones to be achieved. The company may submit a settlement proposal for termination costs by May 7, 2026.

• ·Contract details referenced in Exhibit 10.1 of Spire Global's 8-K filed February 7, 2025
• ·Termination notice from His Majesty the King in right of Canada, as represented by the Minister of Public Works and Government Services (PWGS)

24-04-2026

Peoples Bancorp Inc. announced a definitive Agreement and Plan of Merger dated April 20, 2026, with Citizens National Corporation, under which Citizens will merge with and into Peoples, with Peoples as the surviving entity, followed by a subsidiary bank merger of Citizens Bank of Kentucky into Peoples Bank. Citizens shareholders will receive 2.10 shares of Peoples common stock and $8.00 in cash per Citizens common share as merger consideration. The boards of both companies have approved the transaction, which is intended to qualify as a tax-free reorganization under IRC Section 368(a) and awaits regulatory approvals and shareholder vote.

• ·Agreement executed on April 20, 2026; filed as 8-K on April 24, 2026.
• ·Closing to occur remotely within 30 days after satisfaction of conditions in Article VII.
• ·Requires Requisite Regulatory Approvals and Citizens shareholder approval.
• ·Fairness opinions received by both boards.
• ·Dissenters' rights available to Citizens shareholders under KBCA.
• ·No fractional Peoples shares; cash in lieu based on 10-day VWAP prior to Closing.

24-04-2026

Mitesco, Inc. received $50,000 in bridge financing via a 10% OID convertible note from a new institutional investor, repayable at $55,000, convertible at $0.15 per share. The company issued $60,000 in Series X Preferred Stock each to directors and Anglo Irish Investments, LLC, bringing total outstanding Series X shares to 51,703, and approved equity-heavy FY2026 compensation for CEO Brian Valania ($120,000 base + $120,000 potential bonuses, with $60,000 FY2025 unpaid) and directors ($60,000 Series X + 100,000 options each + potential $25,000 cash on $5M raise). While pursuing a potential acquisition with up to $150,000 in Q2 FY2026 expenses, no assurances exist on terms, financing, or completion.

• ·Series X Preferred ranks pari passu with Series C, senior to Series A and common stock; $25 liquidation preference per share.
• ·Bridge Note maturity: 12 months; sold under Section 4(a)(2) and Regulation D.
• ·New stock options at 115% of closing price when Form S-8 filed.
• ·Acquisition advisor retained April 22, 2025; risks include no assurance on terms, financing, or professional opinions.

24-04-2026

Kartoon Studios, Inc. entered into an agreement with Continuation Capital, Inc. to issue 2,553,047 shares of common stock in exchange for settling past due obligations totaling $1,143,884 plus an additional $315,000. The agreement, approved by the Florida Circuit Court on April 13, 2026, became binding on April 20, 2026, after NYSE American approval. Shares are to be issued at a rate of 1.75 shares per dollar pursuant to a Section 3(a)(10) exemption.

• ·Agreement dated as of April 8, 2026.
• ·Issued at a rate of 1.75 shares per dollar of obligation.
• ·Court approval by Circuit Court of the Twelfth Judicial Circuit in Sarasota County, Florida.

24-04-2026

Cheetah Net Supply Chain Service Inc. amended its Certificate of Incorporation to authorize 2,200,500,000 total shares, including 500,000 shares of Preferred Stock (par value $0.0001) and 2,200,000,000 shares of Common Stock divided into Class A (2,000,000,000 shares, 1 vote per share) and Class B (200,000,000 shares, 15 votes per share, convertible 1:1 to Class A). Effective April 20, 2026, a 1-for-200 reverse stock split applies to outstanding Class A and Class B shares, with fractional shares rounded up to the nearest whole share. The amendment was signed by Huan Liu, Chief Executive Officer, Director, and Chairman.

• ·Original incorporation date: February 2, 2026.
• ·Amendment filed: March 24, 2026 at 10:36 AM.
• ·Amendment signed: March 23, 2026.
• ·Par value per share: $0.0001 for Preferred, Class A Common, and Class B Common Stock.
• ·Reverse Stock Split effective: April 20, 2026 at 8:00 AM Eastern Time.

24-04-2026

AEVEX Holdings, LLC entered into a senior secured Credit Agreement dated April 20, 2026, with Bank of America, N.A. as Administrative Agent and other lenders, providing $100.0 million in Closing Date Term Loans, $75.0 million in Delayed Draw Term Loan Commitments, and $200.0 million in Revolving Commitments. Proceeds from the Closing Date Term Loans and Revolving Borrowings will fund the Transactions, bolster the balance sheet, and support working capital and general corporate purposes, while Delayed Draw Term Loans and additional Revolving Loans will serve similar needs post-Closing Date. No performance declines or flat metrics are reported, as this is a new financing arrangement.

• ·Agreement filed as Exhibit 10.1 in 8-K on April 24, 2026, covering Items 1.01, 1.02, 2.03, and 9.01.
• ·Facilities include provisions for Letters of Credit and Swing Line Loans.

24-04-2026

Standard BioTools Inc. (NASDAQ: LAB) received a Nasdaq notification on April 20, 2026, stating it failed the minimum bid price requirement under Listing Rule 5450(a)(1), with shares closing below $1.00 for 30 consecutive business days. The company has 180 calendar days until October 19, 2026, to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive business days, with no immediate impact on trading or operations. While the company intends to cure the deficiency, potentially via reverse stock split or transfer to Nasdaq Capital Market, success is not assured.

• ·Notification triggers automatic 180-day compliance period under Nasdaq Listing Rule 5810(c)(3)(A)
• ·Potential eligibility for additional 180-day period if transferring to Nasdaq Capital Market, excluding bid price requirement but meeting other standards
• ·Filing signed on April 24, 2026

24-04-2026

Ultra Clean Holdings, Inc. entered into the Tenth Amendment to its Credit Agreement dated April 23, 2026, refinancing and replacing its existing Revolving Facility in full with new Tenth Amendment Revolving Commitments totaling $250,000,000 and extending the maturity date. The amendment also modifies various terms of the agreement, with Barclays Bank PLC continuing as Administrative Agent. All previously-incurred Term Loans have been prepaid in full, along with accrued interest and fees.

• ·Amendment effective upon satisfaction of conditions including executed counterparts, legal opinions, and completion of Refinancing on Tenth Amendment Effective Date
• ·Consenting Lenders constitute all Lenders under Existing Credit Agreement; Tenth Amendment Revolving Lenders constitute all Lenders under Amended Credit Agreement
• ·Schedules updated: 1.1A (Revolving Commitments), 1.1C (L/C Commitments); Schedule 1.1D deleted

24-04-2026

Consumer Portfolio Services, Inc. (CPSS) closed its largest-ever securitization transaction, issuing $514.07 million in asset-backed notes secured by $526.17 million in automobile receivables through CPS Auto Receivables Trust 2026-B. This marks the 59th senior subordinate securitization since 2011 and the 42nd consecutive deal with triple-A ratings on the senior class from Moody’s and DBRS Morningstar. The notes feature a weighted average coupon of 5.51%, with initial credit enhancement of 1.00% cash deposit and 2.30% overcollateralization.

• ·Class A: Average Life 0.68 years, Price 99.99986%, Moody’s Aaa, DBRS AAA
• ·Class B: Average Life 1.81 years, Price 99.98841%, Moody’s Aaa, DBRS AA
• ·Class C: Average Life 2.52 years, Price 99.98836%, Moody’s Aa3, DBRS A
• ·Class D: Average Life 3.30 years, Price 99.98141%, Moody’s Baa2, DBRS BBB
• ·Class E: Average Life 4.04 years, Price 99.96652%, Moody’s NR, DBRS BB
• ·Transaction closed April 22, 2026; private offering not registered under Securities Act of 1933

24-04-2026

Profusa, Inc. (formerly Northview Acquisition Corp.) issued a Senior Secured Convertible Promissory Note to Ascent Partners Fund LLC on April 20, 2026, with a principal amount of $1,111,111.11 for a purchase price of $1,000,000.00, including Original Issue Discount. The note matures on April 20, 2027 and is secured, pursuant to a Securities Purchase Agreement dated February 11, 2025.

• ·Note issued with Original Issue Discount (OID); OID information available from Ben C. Hwang at (415) 655-9861 or BEN.HWANG@PROFUSA.COM beginning ten days after issuance.
• ·This Note is one of a series issued pursuant to the Securities Purchase Agreement dated February 11, 2025.

24-04-2026

Splash Beverage Group, Inc. amended settlement agreements with prior investors, extending the due date for remaining $535,595 payments to June 1, 2026, with 12% interest accruing, and agreed to pay $100,000 in installments by May 15, 2026. Directors Justin Yorke and Robert Nistico resigned effective April 21 and 24, 2026, respectively, with Nistico entering a six-month $5,000/month consulting agreement including 250,000 stock options partially vesting upon a potential Medterra CBD acquisition. The company received a disputed demand letter from Decathlon Alpha IV, L.P. for immediate repayment of $2,833,395.98 under a 2020 loan agreement, secured by company assets.

• ·Settlement agreements originally relate to October 2024 investments claimed breached by the company.
• ·Loan and Security Agreement dated December 24, 2020, with prior default notices on March 18, 2025 and April 8, 2025.
• ·Company disputes the loan demand and has initiated discussions with the lender.

24-04-2026

Forum Markets, Incorporated, a Delaware corporation (likely related to ETHZilla Corp), filed a Certificate of Elimination for its Series B Convertible Preferred Stock (par value $0.0001 per share), eliminating the designation of 1,000,000 shares, none of which were outstanding. The Board approved this via unanimous written consent effective March 24, 2026, with the certificate filed on April 23, 2026, and effective April 24, 2026. This administrative action reverts the shares to authorized but unissued preferred stock status, with no impact on outstanding shares or financials.

• ·Certificate originally filed September 30, 2024.
• ·Signed April 22, 2026; effective 12:01 a.m. ET April 24, 2026.

24-04-2026

On April 20, 2026, Mannatech, Incorporated received a Nasdaq notice for non-compliance with Listing Rule 5550(b)(1) due to stockholders’ equity deficit of $5,223,000 as of December 31, 2025, below the required $2,500,000 threshold, resulting in a $7.7 million deficiency. The company does not meet alternative standards of $35 million market value of listed securities or $500,000 net income, and faces potential delisting but has until June 4, 2026, to submit a compliance plan with possible extension to October 17, 2026. No positive financial metrics or compliance assurances are provided, highlighting significant listing risk.

• ·Company will be added to Nasdaq’s list of non-compliant companies on April 27, 2026, with non-compliance indicator broadcast on market data network.
• ·Opportunity to appeal to Nasdaq Hearings Panel if compliance plan rejected, during which stock remains listed.

24-04-2026

At the 2026 Annual Meeting of Stockholders on April 23, 2026, Motorsport Games Inc. shareholders approved the exercise of warrants issued on July 29, 2024, to purchase up to 949,310 shares of Class A Common Stock, making them exercisable immediately. The warrants include Series A and Series B each for 460,830 shares at $2.17 per share (expiring October 23, 2031, and October 25, 2027, respectively) and 27,650 placement agent warrants at $2.17125 per share. This approval constitutes a material modification to security holder rights and clarifies that the company's repurchase of shares from Driven Lifestyle Group LLC will not trigger a 'Fundamental Transaction' under the warrants.

• ·Warrants issued on July 29, 2024, were not exercisable until stockholder approval on April 23, 2026.

24-04-2026

Senmiao Technology Limited entered into a securities purchase agreement on April 23, 2026, to sell up to 10,000,000 units at $1.10 per unit, for aggregate gross proceeds of approximately $11,000,000 if fully subscribed. Each unit consists of one share of common stock (par value $0.0001) and four warrants, each exercisable for one share at $1.46 per share until 2031. The net proceeds will fund working capital and general corporate purposes, subject to stockholder approval and customary closing conditions; the offering relies on Regulation D exemption.

• ·Closing subject to stockholder approval for issuance of shares.
• ·Warrants exercisable from Initial Exercise Date until 5:00 p.m. (NYC time) on Termination Date in 2031.
• ·Investors are accredited or sophisticated; no registration required under Securities Act via Regulation D exemption.
• ·Forms of SPA and Warrant filed as Exhibits 10.1 and 10.2.

24-04-2026

On April 20, 2026, Nuvve Holding Corp. received a Nasdaq notice stating its common stock closed below $1.00 per share for 30 consecutive trading days, violating Listing Rule 5550(a)(2). Due to prior reverse stock splits with a cumulative ratio of 250 shares or more to one over the past two years, the Company is ineligible for a compliance period, facing trading suspension on April 29, 2026, unless it appeals by April 27, 2026. The Company plans to appeal and pursue compliance measures, but there is no assurance of success.

• ·Notice issued under Nasdaq Listing Rule 5810(c)(3)(A)(iv) due to prior reverse splits.
• ·Appeal to Nasdaq Hearings Panel stays suspension pending hearing and any extension.
• ·Compliance prior to hearing could moot the process.

24-04-2026

urban-gro, Inc. entered into an Assignment and Assumption Agreement effective April 2026, under which GROW HILL LLC assigns its rights, title, and interest in certain Assigned Items (including a promissory note, Loan Agreement, and Security Agreement) to HUDSON GLOBAL VENTURES, LLC for an Assignment Price of $2,__________ (exact amount redacted). urban-gro acknowledges its ongoing default under the Loan Documents, releases the Assignor from prior obligations, and recognizes the Assignee as successor-in-interest, with the related Denver Lawsuit (Case No. 25CV33546) to be dismissed without prejudice upon payment. While this substitutes the creditor and facilitates litigation dismissal, it underscores urban-gro's Event of Default and continued obligations under the unamended Loan Documents.

• ·Litigation: District Court of Denver, Colorado, Case No. 25CV33546 (Grow Hill LLC as lender, urban-gro as borrower)
• ·Assignee's holding period of the Note tacks back to October 1, 2024, for Rule 144 purposes
• ·Agreement acknowledges Assigned Items as a 'security' under the Securities Act of 1933
• ·Dismissal of Denver Lawsuit required within three business days of Assignor receiving Assignment Price
• ·Indemnity claims against Assignor must be commenced within one year of Effective Date

24-04-2026

On April 24, 2026, Scott M. Sutton resigned as a member of the Board of Directors of Rayonier Advanced Materials Inc. (RYAM) and withdrew as a director nominee for the company's 2026 Annual Meeting of Stockholders. The filing provides no additional details regarding the reasons for the resignation or any compensatory arrangements.

• ·Filing submitted under Item 5.02(b) of Form 8-K.
• ·Company incorporated in Delaware, principal office in Jacksonville, Florida.

24-04-2026

On April 20, 2026, The Joint Corp. entered into an Asset Purchase Agreement with Elite Chiro Group to sell assets and grant franchise rights for 45 company-owned or managed clinics in Southern California for an aggregate purchase price of $2.3 million, subject to adjustments. The deal includes prorated franchise fees under 45 separate agreements and non-exclusive development rights for 10 additional clinics. Elite Chiro Group paid a $150,000 non-refundable down payment, with the balance escrowed and released per clinic closing, conditioned on lease assignments and customary conditions.

• ·Closing of each clinic requires assignment of the existing lease.
• ·Transaction subject to customary closing conditions.
• ·Purchase Price includes prorated franchise fees pursuant to 45 separate franchise agreements.

24-04-2026

Equifax Inc. entered into the Fourth Amendment to its Credit Agreement (originally dated August 25, 2021), effective April 23, 2026, which extends certain revolving commitments to a 2029 maturity date for participating lenders while others remain at 2028. The amendment also increases the aggregate revolving commitments by $500,000,000 through new incremental commitments from designated lenders, which will have identical terms to the 2029 commitments. JPMorgan Chase Bank, N.A. acts as Administrative Agent, with other banks as joint lead arrangers.

• ·Previous amendments dated March 21, 2023 (First), May 24, 2024 (Second), and May 27, 2025 (Third).
• ·Conditions for effectiveness include no Default or Event of Default, true representations and warranties, and payment of fees/expenses.
• ·Schedules 1-A (2026 Incremental Commitments) and 1-B (post-amendment Revolving Commitments) define lender allocations.

24-04-2026

MarketWise, Inc. and MarketWise, LLC entered into a Settlement Agreement on April 21, 2026, with former CEO Mark P. Arnold and JAMA 2021, LLC, resolving prior arbitration claims via a $12,160,000 one-time cash payment and redemption of 520,867 common units. This eliminates future Tax Receivables Agreement (TRA) payment obligations and litigation risk, providing strategic focus, but incurs a significant immediate cash outflow. The agreement includes mutual releases and no admission of liability.

• ·Settlement resolves arbitration demand previously disclosed in 2024 and 2025 Form 10-K filings.
• ·Company agrees to indemnify Mr. Arnold for certain possible tax implications related to arbitration claims.
• ·Tax Receivables Agreement dated July 21, 2021, rights waived by Arnold Parties.

24-04-2026

Citius Pharmaceuticals, Inc. (Nasdaq: CTXR) announced a registered direct offering of 5,076,143 shares of common stock (or pre-funded warrants) at $0.985 per share, priced at-the-market under Nasdaq rules, expected to generate approximately $5 million in gross proceeds before deducting fees. In a concurrent private placement, the company will issue unregistered warrants to purchase up to 5,076,143 shares at an exercise price of $0.86 per share, exercisable immediately and expiring five years after registration statement effectiveness. Net proceeds will support the LYMPHIR™ commercial launch, milestone/regulatory payments, development of product candidates like Mino-Lok® and Halo-Lido, and general corporate purposes.

• ·Closing expected on or about April 24, 2026, subject to customary conditions.
• ·LYMPHIR™ launched by Citius Oncology in December 2025 for relapsed or refractory Stage I–III CTCL.
• ·Shelf registration statement (File No. 333-277319) filed February 23, 2024, effective March 1, 2024.
• ·Pivotal Phase 3 trial for Mino-Lok® and Phase 2b for Halo-Lido completed in 2023; Mino-Lok® met primary/secondary endpoints.

24-04-2026

NEONC Technologies Holdings, Inc. entered into a fourth Securities Purchase Agreement on April 20, 2026, to issue up to 406,694 shares of common stock at $7.20 per share and warrants for up to 406,694 shares at $9.00 exercise price, with an initial closing of 277,777 shares and warrants for approximately $2 million. Proceeds will fund NEO216 preclinical trials, following prior agreements that raised $10 million, $621,804.11, $1,450,004, and $1 million respectively. No performance declines or flat metrics reported in this financing update.

• ·All Securities issued pursuant to Section 4(a)(2) exemption under Securities Act.
• ·Resale registration statement for Shares and Warrant shares to be filed no later than 10 days after initial closing of fourth Agreement.
• ·Fourth Securities Purchase Agreement offering terminates on April 30, 2026.
• ·Common Stock par value: $0.0001 per share.
• ·Trading symbol: NTHI on Nasdaq Stock Market LLC.

24-04-2026

Electro-Sensors, Inc. entered into a Merger Agreement on April 20, 2026, with steute Industrial Controls, Inc. (Parent) and its subsidiary Steute Burwell, Inc., under which the Company will merge with Merger Sub and become a wholly owned subsidiary of Parent, with shareholders receiving $7.75 per share in cash. The board approved the agreement and recommends shareholder approval, subject to customary closing conditions including shareholder vote, no more than 10% exercising dissenters' rights, and ESOP approval. A $1,000,000 termination fee plus up to $300,000 in expenses may apply if terminated under certain circumstances, highlighting execution risks.

• ·Closing conditions include accuracy of representations and warranties, no material adverse effect post-agreement, Support Agreements remaining in effect, ESOP vote completion, and cancellation of all Company Options.
• ·Certain board members and beneficial owners entered into Support Agreements to vote in favor of the Merger.

24-04-2026

Palomino Laboratories Inc. completed an initial closing of a private placement on April 20, 2026, selling 3,773,853 shares of common stock at $4.00 per share for gross proceeds of $15,095,412, with potential additional closings up to a total of $30,000,000 by April 30, 2026. The Placement Agent, Laidlaw & Company (UK) Ltd., receives 10% cash fee on introduced proceeds, 5% on company-introduced, plus expense reimbursements and warrants equal to 10% of agent-introduced shares exercisable at 120% of the offering price. The company entered into Registration Rights Agreements obligating it to file an S-1 resale registration statement promptly, with effectiveness targeted within 120 days.

• ·Additional closings possible until April 30, 2026, at discretion of Company and Placement Agent.
• ·Investors in subsequent closings must affirm pre-existing relationship and no awareness from public disclosures.
• ·Company to file Form S-1 for resale registration as soon as commercially reasonable, effective within 120 days; piggyback rights and provisions for reduction securities.
• ·Separate Laidlaw Registration Rights Agreement for Form S-3 when eligible.

24-04-2026

Apollo Asset Backed Credit Co LLC disclosed its monthly Net Asset Value as of March 31, 2026, totaling $1,824,098 thousand across 71,285,396 outstanding shares. Key components include investments at fair value of $1,729,186 thousand (cost basis $1,720,592 thousand), cash and equivalents of $138,304 thousand, offset by other liabilities of $180,469 thousand. Net asset value per share ranged from $24.96 to $25.98 across various Series I and II share classes.

• ·Distribution payable: $14,595 thousand
• ·Accrued performance fee: $2 thousand
• ·Management fee payable: $1,364 thousand
• ·Other assets: $153,038 thousand
• ·NAV per share examples: Series I A-I Shares $25.20 (1,647,846 shares), Series II F-I Shares $25.50 (16,439,415 shares)

24-04-2026

Helix Energy Solutions Group, Inc. (HLX) signed an Agreement and Plan of Merger on April 22, 2026, to acquire Hornbeck Offshore Services, Inc. through a two-step merger process: first, Helix's subsidiary Odyssey Sub, Inc. merges into Hornbeck (surviving as a wholly owned subsidiary), followed immediately by a merger into Hercules Sub LLC. Prior to closing, Helix will convert from a Minnesota to a Delaware corporation; both boards unanimously approved the tax-free reorganization, recommending shareholder approval, with no dissenting shares or negative performance metrics disclosed.

• ·Closing to occur on the third Business Day after satisfaction of conditions in Article VIII, at 9:00 a.m. Eastern time via electronic exchange.
• ·Parent consents executed concurrently or immediately after signing.
• ·Transaction intended as tax-free reorganization under IRC Section 368(a).

24-04-2026

NexGel, Inc. received a deficiency notice from Nasdaq on April 22, 2026, stating that its common stock (NXGL) bid price was below the $1.00 minimum for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days until October 19, 2026, to regain compliance by closing at $1.00 or higher for 10 consecutive business days, with no immediate impact on trading. Failure to comply risks delisting, potentially after a second 180-day period, and the company may pursue a reverse stock split but offers no assurance of success.

• ·Nasdaq Listing Rule 5810(c)(3)(A) governs the compliance period.
• ·Second compliance period requires meeting market value of publicly held shares and other initial listing standards.
• ·Company address: 2150 Cabot Boulevard West, Suite B, Langhorne, Pennsylvania 19047.
• ·Emerging growth company status confirmed.

24-04-2026

Odyssey Health, Inc. closed a definitive sub-license agreement granting its subsidiary exclusive worldwide marketing and distribution rights for BreastCheck™, a non-invasive at-home breast cancer screening device, positioning the company to enter the $26 billion global market with commercial sales anticipated in the second half of 2026. BreastCheck™ provides results in 15 minutes, is registered with the FDA, EU, and UK authorities, and aims to drive recurring revenue as a first-line screening tool adjunct to mammography. CEO Michael Redmond emphasized its role in the company's transition to revenue-generating products.

• ·BreastCheck™ detects breast abnormalities via temperature averaging across three areas per breast using a mobile app.
• ·Breast cancer accounts for roughly 30% of new cancers among women in the US.
• ·Forward-looking statements highlight risks including manufacturing, commercialization timelines, financing, and market conditions.

24-04-2026

Medicus Pharma Ltd. amended its Equity Distribution Agreement with Maxim Group LLC and Yorkville Securities, LLC, increasing the ATM offering aggregate amount from $15,349,674 to $50,000,000, and has raised approximately $11.5 million to date. However, on April 21, 2026, the company received a Nasdaq notice for noncompliance with the minimum $1.00 bid price rule over 30 consecutive business days, providing 180 days until October 19, 2026, to regain compliance by achieving $1.00+ for 10 consecutive business days.

• ·Nasdaq compliance grace period: 180 calendar days from April 21, 2026, until October 19, 2026; potential second 180-day period available.
• ·Prospectus supplement filed April 23, 2026, to shelf registration statement (No. 333-292475).
• ·No immediate effect on listing or trading of shares on Nasdaq Capital Market.

24-04-2026

ALT5 Sigma Corporation entered into a Stock Exchange Agreement on April 20, 2026, to acquire Block Street Corp. by issuing 12,670,257 shares of common stock valued at $12 million and granting pre-funded warrants exercisable for up to 15,837,821 shares ($15 million initial exercise price) and 16,893,675 shares ($16 million initial exercise price), vesting upon achieving $20 million trailing net revenues and $8 million Modified Operating Income, respectively. The company also signed a binding letter of intent to acquire Decentralized Technologies Inc. (Dectec) for 4 million shares initially, plus up to 4 million additional shares based on $20 million in Gross Profit over 36 months. Shares are subject to 24-month lock-up with phased releases and leak-out provisions limiting daily sales to 10% of average trading volume.

• ·Warrants exercisable at remaining $0.001 per share after initial exercise price payment.
• ·Lock-up period of 24 months for issued shares and warrant shares, with 25% releases every six months starting April 20, 2026.
• ·Leak-out limits sales to 10% of average daily trading volume over prior 20 trading days; non-cumulative.
• ·Dectec additional shares issued at 1 million shares per $5 million Gross Profit, up to $20 million over 36 months.
• ·Transactions conducted as private placements under Section 4(a)(2) of the 1933 Act; no registration obligation.

24-04-2026

Surf Air Mobility Inc. (the 'Company'), along with subsidiaries Southern Airways Express, LLC and Southern Airways Pacific, LLC (collectively, 'Borrowers'), entered into a promissory note dated April 20, 2026, with LamVen LLC for advances up to $15,000,000, secured by a pledge on all aircraft collateral (excluding certain assets). The note includes a $1,500,000 non-refundable origination fee (payable in cash or unregistered common stock at $1.274 per share) and 12.5% annual interest (also payable in cash or stock), with monthly interest payments and a 36-month maturity. Draw periods allow up to $5,000,000 every 90 days, subject to lender discretion and a 9.99% beneficial ownership limit on stock issuances.

• ·Maturity Date: 36 months from April 20, 2026, or earlier upon acceleration.
• ·Prepayment allowed in whole or in part without premium or penalty upon 3 business days' notice.
• ·Advances funded within 3 business days of request to Company, Borrower, or subsidiary account.
• ·Negative pledge on Collateral except Permitted Liens during term.

24-04-2026

Zeo Energy Corp. received a notice from Nasdaq on April 23, 2026, stating that its Class A common stock (ZEO) failed to maintain a $1 minimum bid price for 30 consecutive business days, violating Nasdaq Listing Rule 5550(a)(2). The company has a 180-day compliance period until October 20, 2026, to regain compliance by achieving a $1+ closing bid price for 10 consecutive business days, with no immediate impact on listing. Failure to comply could lead to delisting, though the company plans to monitor the stock price and explore options.

• ·Compliance period ends October 20, 2026; potential second 180-day period eligibility if meeting other standards by October 14, 2026.
• ·Notification has no immediate effect on listing; appeal possible to Nasdaq Hearings Panel if delisting notice issued.
• ·Company address: 7625 Little Rd, Suite 200A, New Port Richey, FL 34654.

24-04-2026

Universal Health Services, Inc. executed the Eleventh Amendment and Increased Facility Activation Notice to its Credit Agreement dated November 15, 2010, effective upon satisfaction of conditions around April 22, 2026, adding $200,000,000 in incremental revolving commitments, $300,000,000 in incremental term loan commitments, and $400,000,000 in delayed draw term loan commitments, for a total of $900,000,000 in new facilities maturing September 26, 2029. The amendment includes replacement of non-consenting lenders, removal of credit adjustment spreads, and updates to schedules and terms aligning with existing facilities. No declines or flat performance metrics were reported, enhancing borrowing capacity without noted drawbacks.

• ·Amendment dated April 22, 2026; Filing Date April 24, 2026.
• ·2026 Incremental Term Loans amortize in quarterly installments starting September 30, 2026; Delayed Draw Term Loans do not amortize.
• ·Applicable margins align with existing Revolving Loans and Tranche A Term Loans.
• ·Involves lender replacements for non-consenting lenders and consents from all post-replacement lenders.

24-04-2026

Humacyte, Inc. amended its distribution agreement with Fresenius Medical Care, realigning ex-U.S. rights to Symvess to grant Humacyte exclusive distribution rights outside the U.S., while FME receives low-single-digit royalties on Humacyte's net sales ex-U.S.; U.S. terms remain unchanged. This positions Humacyte to advance commercial initiatives in the Kingdom of Saudi Arabia and Israel for vascular injury repair and other indications, and to pursue discussions with new corporate partners for international and indication-specific rights. The move is described as beneficial for both companies to support Humacyte's international expansion.

• ·FDA approved Humacyte’s Biologics License Application for ATEV in extremity vascular trauma indication in December 2024.
• ·ATEVs in late-stage clinical trials for arteriovenous (AV) access for hemodialysis and peripheral artery disease (PAD).
• ·Humacyte’s 6mm ATEV for AV access received FDA Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations.
• ·6mm ATEV for urgent arterial repair following extremity vascular trauma and advanced PAD also received RMAT designations.
• ·ATEV received priority designation for vascular trauma by the U.S. Secretary of Defense.

24-04-2026

Gladstone Land Corporation and its operating partnership entered into amended and restated Equity Distribution Agreements with Virtu Americas LLC and Lucid Capital Markets, LLC, enabling at-the-market sales of up to $500.0 million in common stock. Sales agents will receive up to 3.0% compensation on gross proceeds, with no obligation to sell any shares. The offering is pursuant to an S-3 registration statement, with a prospectus supplement filed on April 24, 2026.

• ·Shares may be sold on Nasdaq Global Market, other trading markets, or via privately negotiated transactions.
• ·Registration Statement on Form S-3 (File No. 333-294917).
• ·Prospectus supplement dated April 24, 2026, to base prospectus dated April 23, 2026.
• ·Legal opinion from Venable LLP (Exhibit 5.1) and tax opinion from Squire Patton Boggs (US) LLP (Exhibit 8.1).

24-04-2026

Universal Health Realty Income Trust (UHT) entered into the First Amendment to its Second Amended and Restated Credit Agreement on April 21, 2026, originally dated September 30, 2024, administered by Wells Fargo Bank as agent. The amendment provides new First Amendment Term Loan Commitments totaling $50,000,000 from certain lenders. Effectiveness is subject to standard closing conditions including executed documents, officer certificates, legal opinions, solvency certification, and no defaults.

• ·Amendment amends Schedule 2.1(b) and incorporates changes shown in Annex A.
• ·Requires joinder of Additional Subsidiary (listed on Annex C) to Subsidiary Guaranty and Pledge Agreement.
• ·SEC filing date: April 24, 2026; Items 1.01, 2.03, 9.01.

24-04-2026

MeiraGTx Holdings plc completed the initial closing on April 20, 2026, of a strategic collaboration with Hologen Limited, including amendments to the Neuro and Manufacturing Framework Agreements (dated March 9, 2025) and a new Collaboration and License Agreement for AAV-GAD gene therapy for Parkinson’s disease, AAV-BDNF for genetic obesity disorders (Clinical Programs), and a proprietary Delivery Device. The transaction involves a $200 million Upfront Payment, with $105 million already paid by Hologen, enabling Hologen to acquire 70% ownership of Hologen Neuro AI Limited (HNAI) post-Completion and a minority interest in MeiraGTx Manufacturing with an option to increase to 40%. No performance declines noted in this non-financial filing.

• ·Hologen’s option to purchase additional shares in MeiraGTx Manufacturing to reach up to 40% ownership granted on Additional Share Purchase closing date and expires 12 months thereafter.
• ·MeiraGTx’s option to repurchase all Hologen shares in MeiraGTx Manufacturing at Hologen’s purchase price begins on third anniversary of Additional Share Purchase closing and ends three years thereafter.
• ·Exhibits include Deed of Amendment to Neuro Framework Agreement (10.1), Deed of Amendment to Manufacturing Framework Agreement (10.2), and Collaboration and License Agreement (10.3).